Adenosine A2a receptor antagonists

US6630475B2 · kind B2 · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Bernard R. Neustadt · West Orange, US
• Neil A. Lindo · New Providence, US
• William J. Greenlee · Teaneck, US
• Deen Tulshian · Lebanon, US
• Lisa S. Silverman · Edison, US
• Yan Xia · Edison, US
• Craig D. Boyle · Readington, US
• Samuel Chackalamannil · Califon, US

Key dates

• Filing date: May 24, 2001
• Grant date: Oct 7, 2003
• Expiry date: Jul 27, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, whereinR is optionally substituted phenyl, cycloalkenyl, or heteroaryl;X is alkylene or —C(O)CH2—;Y is —N(R2)CH2CH2N(R)3)—, —OCH2CH2N(R2)—, —O—, —S—, —CH2S—, —(CH2)2—NH—, or optionally substituted  m and n are 2-3, and Q is nitrogen or optionally substituted carbon; andZ is optionally substituted phenyl, phenylalkyl or heteroaryl, diphenylmethyl, R6—C(O)—, R6—SO2—, R6—OC(O)—, R7—N(R8)—C(O)—, R7—N(R8)—C(S)—,  phenyl-CH(OH)—, or phenyl-C(═NOR2)—; or when Q is CH, phenylamino or pyridylamino; orZ and Y together are substituted piperidinyl or substituted phenyl; andR2, R3, R6, R7, and R8 are as defined in the specification are disclosed, their use in the treatment of Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them; also disclosed are a processes for preparing intermediates useful for preparing compounds of formula I…